Navigation Links
Brain Tumor Vaccine Shows Promise in Early Trial
Date:4/17/2012

By Maureen Salamon
HealthDay Reporter

TUESDAY, April 17 (HealthDay News) -- A vaccine made from brain cancer patients' own tumor cells led to a nearly 50 percent improvement in survival times for those stricken with glioblastoma multiforme, the same malignancy that claimed the life of U.S. Sen. Edward Kennedy, a new study suggests.

A phase 2 multicenter trial of about 40 patients with recurrent glioblastoma -- an aggressive brain cancer that typically kills patients within 15 months of diagnosis -- showed that the vaccine safely increased average survival to nearly 48 weeks, compared with about 33 weeks among patients who didn't receive the treatment. The six-month survival rate was 93 percent for the vaccinated group, compared with 68 percent for 86 other glioblastoma patients, who were treated with other therapies.

"We've done a lot of things for this kind of tumor in the last 40 or 50 years, all variations on different chemotherapies that haven't really panned out," said Dr. Jonas Sheehan, director of neuro-oncology at the Penn State Cancer Institute, who was not involved in the study. "What we've known needed to happen for a while now is a revolution -- a totally new way of approaching these tumors. This is an example of a totally new paradigm."

The study is scheduled to be presented Tuesday at the annual meeting of the American Association of Neurological Surgeons (AANS), in Miami.

About a quarter of the 18,500 brain tumors diagnosed each year are glioblastomas, which are more common in men and typically occur between the ages of 50 and 70, according to the AANS. Kennedy died of the malignancy in 2009, 15 months after his diagnosis. Surgery, radiation and chemotherapy are among the standard treatment options.

The vaccine used in the trial, known as HSPPC-96, was created with tumor cells from patients who had undergone surgery to remove as much tumor as possible. The vaccine was then injected into their bodies to induce an immune response against the tumor, said lead investigator Dr. Andrew Parsa, vice chairman of neurological surgery at University of California, San Francisco. Side effects among participants were minimal.

"It's the concept of chronic therapy, to turn this into a chronic disease like hypertension and diabetes," said Parsa, who noted that no drug companies funded the study. "It's the only therapy in the clinical realm that has a reasonable chance of doing this, because we can't give patients chemotherapy [because of toxicity] for unlimited amounts of time."

Parsa said the vaccine's impact, if validated with a randomized study in the near future, could be a "total game-changer."

Added Sheehan: "The hope is that we'll go from a survival of 15 months to a meaningful difference. We're looking to go from 15 months to five years, a quantum leap forward."

Because this study was to be presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Visit the American Association of Neurological Surgeons for more on glioblastomas.

SOURCES: Andrew Parsa, M.D., Ph.D., professor and vice chairman, neurological surgery, University of California, San Francisco; Jonas Sheehan, M.D., director, neuro-oncology, Penn State Cancer Institute, Hershey, Pa.; April 17, 2012, presentation, abstract, American Association of Neurological Surgeons, annual meeting, Miami


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Football-related catastrophic brain injuries on the rise
2. Researchers Map Brain Regions Linked to Intelligence
3. Nonsurgical Method to Measure Brain Pressure Shows Promise
4. Dental X-Rays May Be Linked to Benign Brain Tumors
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Why is traumatic brain injury increasing among the elderly?
7. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
8. Epilepsy Leads to More Brain Abnormalities Over Time
9. Study Suggests Vaccine May Help Kids With Brain Cancer
10. Our brains on food: From anorexia to obesity and everything in between
11. Northwestern study compares endovascular brain aneurysm repair devices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Brain Tumor Vaccine Shows Promise in Early Trial
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... surgeon reveals that infants born with severe congenital diaphragmatic hernia have better survival ... born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... won the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan ... the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage ... gene-based immunotherapeutics and vaccines for the treatment of cancer & ... 3rd Annual Growth Capital Expo to be held ... Caesars Palace in Las Vegas, Nevada.  The Company presentation ... th by Dr. John N. Bonfiglio a ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)...   Zillion Group today announced the ... which specializes in live video consultation. Turning content, ... Zillion enables companies to realize the true potential ... control of their health. Zillion,s ... one-to-one, group and webcast scheduled or on-demand – ...
Breaking Medicine Technology: